Trump Administration Finalizes 14 Drug Price Deals, Unveils 2026 Launch for Direct-to-Consumer TrumpRX Platform
President Trump secured 14 drug price agreements, including 9 new deals, to lower U.S. prescription costs for Medicaid and uninsured patients. TrumpRX launches early 2026.
PBS NewsHourNews Wrap: 9 pharmaceutical companies cut drug prices for Medicaid
ABC NewsTrump announces lower drug price deals with 9 pharmaceutical companies
Boston HeraldTrump announces lower drug price deals with 9 pharmaceutical companies
NBC NewsNine drugmakers cut deal with Trump administration to slash medication costs
Overview
President Trump announced agreements with nine new drugmakers, bringing the total to 14 deals, to significantly lower U.S. prescription drug costs by aligning prices with other developed nations.
These agreements will implement 'most-favored-nation' pricing nationwide, benefiting all markets including commercial, cash pay, Medicare, and Medicaid, ensuring more affordable options for patients.
Bristol Myers Squibb will provide its profitable blood thinner, Eliquis, free to Medicaid to reduce blood clot and stroke risks, while other deals target drugs for asthma, cancers, and HIV.
Participating pharmaceutical companies, including Amgen and Merck, will receive a three-year tariff exemption in exchange for their commitments to lower prices and potentially donate ingredients for a national reserve.
The Trump administration plans to launch TrumpRX, a federal direct-to-consumer website, in early 2026, allowing consumers to purchase pharmacy-ready medicines directly from manufacturers at set prices.
Analysis
Center-leaning sources cover this story neutrally, focusing on reporting the facts of the Trump administration's deal with drugmakers. They clearly attribute all claims to the White House or specific officials and include expert analysis that questions the deal's potential impact, demonstrating balanced reporting. The language used is objective, avoiding loaded terms or evaluative descriptions.